1Devereux R B, Lutas E M, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol, 1984, 4:1222--1230.
2Ichiki T, Usui M, Kato M, et al. Downregulation of angiotensin Ⅱ type I receptor gene transcription by nitric oxide. Hypertension, 1998, 31 :342-- 346.
3Ruiz-Gayo M, Somoza B, Bravo R, et al. Chronic losartan treatment decreases angiotensin Ⅱ -mediated facilitation of noradrenaline release in the caudal artery of spontaneously hypertensive rats. Life Sci, 2000, 67:3153--3162.
4Bode-Boger S M, Boger R H, Kielstein J T, et aL Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis. J Investig Med, 2000,48 : 125-132.
5Nakamura T, Kurashina T, Saito Y, et al. ET(A) receptor antagonists ameliorates nephrosclerosis and left ventricular hypertrophy induced in rat by prolonged inhibition of nitric oxide synthesis. Hypertens Res, 1998,21:251--257.
6Millatt L J, Abdel-Rahman E M, Siragy H M, et al.Angiotensin Ⅱ and nitric oxide: a question of balance.Regul Pept, 1999, 81:1--10.
7Marcus G. Hennersdorf,Gerd J. Hafke,Stephan Steiner,Stefan Dierkes,A. Jansen,Christian Perings,Bodo E. Strauer. Determinanten des paroxysmalen Vorhofflimmerns bei Patienten mit arterieller Hypertonie[J] 2003,Zeitschrift für Kardiologie(5):370～376
